Apogee Therapeutics Director Mark McKenna Acquires $990,775 in Stock

InvestingDec 16 19:14

Guggenheim Reiterates Buy on Apogee Therapeuticsto Buy

BenzingaDec 12 23:43

Apogee Therapeutics Advances Clinical Trials for APG333

TipRanksDec 10 20:59

Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025

BreakingsDec 10 20:00

Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions

BreakingsDec 10 20:00

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, Its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

GlobeNewswireDec 10 20:00